Submitted for Publication: August 15, 2013; final revision received January 16, 2014; accepted February 3, 2014.
Published Online: May 7, 2014. doi:10.1001/jamapsychiatry.2014.243.
Study concept and design: Chiappelli, Pocivavsek, Kochunov, Schwarcz, Hong.
Acquisition, analysis, or interpretation of data: Chiappelli, Pocivavsek, Nugent, Notarangelo, Kochunov, Rowland, Hong.
Drafting of the manuscript: Chiappelli, Pocivavsek, Kochunov, Hong.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Chiappelli, Nugent, Kochunov, Hong.
Obtained funding: Schwarcz, Hong.
Administrative, technical, or material support: Pocivavsek, Notarangelo, Kochunov, Schwarcz, Hong.
Study supervision: Schwarcz, Hong.
Conflict of Interest Disclosures: Drs Schwarcz and Hong have submitted a patent application for the use of salivary KYNA as a biomarker. No other disclosures were reported.
Funding/Support: This work was supported by grants R01MH085646 (Dr Hong), R01DA027680 (Dr Hong), R21DA033817 (Dr Hong), R01EB015611 (Dr Kochunov), and T32MH067533 (Drs Chiappelli and Rowland) from the National Institutes of Health.
Role of the Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.